
Adverse Events and Oncotargeted Kinase Inhibitors
Description
Key Features
- Offers a unique and comprehensive publication on the adverse events associated with a new and fast-growing class of medicines
- Provides a systematic analysis of adverse events aimed at better prevention through understanding and offering insights for the development of safer drugs
- Uses practical guidelines to establish a leading reference on this class of drugs for educators, researchers, drug developers, clinicians, safety professionals, and more
Readership
Intended for pharmacologists, clinicians and specialists including oncologists, drug safety control officials and drug developers and producers who are working to find effective molecules with the lowest adverse effects profiles; academics involved in drug safety issues and public health professionals
Table of Contents
Part I: General Aspects
1. Introduction
2. Protein and Lipid Kinases
3. Kinase Inhibitors
4. Adverse EventsPart II: Oncotargeted Kinase Inhibitors
5. Imatinib
6. Gefitinib
7. Erlotinib
8. Sorafenib
9. Sunitinib
10. Dasatinib
11. Lapatinib
12. Nilotinib
13. Pazopanib
14. Vandetanib
15. Vemurafenib
16. Crizotinib
17. Ruxolitinib
18. Axitinib
19. Bosutinib
20. Regorafenib
21. Cabozantinib
22. Ponatinib
23. Dabrafenib
24. Trametinib
25. Adatinib
26. Idelalisib
27. IbrutinibPart III: Overview
28. Kinase Inhibitors as Adverse Event Inducers
29. Kinase Inhibitors as Drug Class Events
30. Conclusion and Perspectives
Product details
- No. of pages: 736
- Language: English
- Copyright: © Academic Press 2017
- Published: May 8, 2017
- Imprint: Academic Press
- eBook ISBN: 9780128094457
- Hardcover ISBN: 9780128094006
About the Author
Giuseppe Tridente
School of Medicine and Surgery
Coordinator of the Teachers’ Committee for the Master in Translational Biomedicine
Universita degli Studi di Verona, Italy
Affiliations and Expertise
Ratings and Reviews
There are currently no reviews for "Adverse Events and Oncotargeted Kinase Inhibitors"